AGN — Argenica Therapeutics Cashflow Statement
0.000.00%
- AU$36.61m
- AU$26.05m
- AU$0.51m
Annual cashflow statement for Argenica Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0 | 0.002 | 0.781 | 0.666 | 0.919 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -1.05 | -3.36 | -3.3 | -5.06 | -5.7 |
Other Investing Cash Flow Items | — | — | -0.05 | 0.05 | 0 |
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Cash from Investing Activities | — | — | -0.05 | 0.05 | 0 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 7.85 | 5.13 | 3.73 | 11.6 | 0.347 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 6.8 | 1.77 | 0.375 | 6.62 | -5.36 |